Related Experiment Video
Updated: May 18, 2026
Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
Published on: August 25, 2022
Rescuing the neonatal brain from hypoxic injury with autologous cord blood
1Department of Pediatrics, New York Medical College, Valhalla, NY 10595, USA.
Insights
Hypothermia therapy helps infants with perinatal hypoxic-ischemic encephalopathy (HIE), but adjunct therapies like cord blood stem cells are needed. Further research will determine optimal strategies for cord blood stem cell therapy in HIE.
Area of Science:
- Neonatal neurology
- Regenerative medicine
- Perinatal medicine
Background:
- Perinatal hypoxic-ischemic encephalopathy (HIE) causes infant mortality and long-term neurological disability.
- While hypothermia therapy improves outcomes, ~40% of neonates with HIE still experience death or significant impairment.
- Adjunct therapies are crucial to enhance neuroprotection in neonates with HIE.
Purpose of the Study:
- To explore the potential of cord blood (CB) stem cells as an adjunct therapy for neonatal hypoxic-ischemic encephalopathy (HIE).
- To review the current research on CB stem cell administration in HIE animal models and ongoing clinical trials.
- To identify key areas for future research to optimize CB stem cell therapy for HIE.
Main Methods:
- Review of animal models of HIE treated with human CB cells.
- Analysis of ongoing pilot studies investigating autologous CB infusion in neonates with HIE and children with cerebral palsy.
- Discussion of potential mechanisms of action for CB stem cells, including anti-inflammatory effects, neurotrophic factor release, and neurogenesis stimulation.
Main Results:
- Animal models suggest CB stem cell administration improves outcomes in HIE.
- Pilot studies indicate autologous CB infusion is safe in neonates with HIE and children with cerebral palsy.
- Efficacy of CB stem cell therapy requires evaluation through ongoing placebo-controlled trials.
Conclusions:
- Cord blood stem cells show promise as an adjunct therapy for HIE.
- Further research is essential to determine optimal strategies for CB stem cell therapy, including timing, dosage, delivery route, cell type, and ex vivo modifications.
- Improving neuroprotection and long-term outcomes in HIE survivors necessitates continued investigation into novel therapeutic approaches.
Abstract:
Brain injury resulting from perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality in infants and chronic neurologic disability in surviving children. Recent multicenter clinical trials demonstrated the effectiveness of hypothermia initiated within the first 6 postnatal hours to reduce the risk of death or major neurological disabilities among neonates with HIE. However, in these trials, approximately 40% of cooled infants died or survived with significant impairments. Therefore, adjunct therapies are required to improve the outcome in neonates with HIE. Cord blood (CB) is a rich source of stem cells. Administration of human CB cells in animal models of HIE has generally resulted in improved outcomes and multiple mechanisms have been suggested including anti-inflammation, release of neurotrophic factors and stimulation of endogenous neurogenesis. Investigators at Duke are conducting studies of autologous CB infusion in neonates with HIE and in children with cerebral palsy. These pilot studies indicate no added risk from the regimens used, but results of ongoing placebo-controlled trials are needed to assess efficacy. Meanwhile, further investigations are warranted to determine the best strategies, that is, timing, dosing, route of delivery, choice of stem cells and ex vivo modulations, to attain long-term benefits of CB stem cell therapy.
